The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Baricitinib Is Effective in Patients Treated with DMARDs & Methotrexate

Baricitinib Is Effective in Patients Treated with DMARDs & Methotrexate

January 30, 2017 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Baricitinib is a once-daily oral Janus kinase 1 (JAK1)/JAK2 inhibitor in development to treat patients with moderate to severe rheumatoid arthritis  (RA). Because many patients who suffer from chronic inflammatory rheumatic diseases may also have comorbidities, physicians have asked whether baricitinib is an effective treatment in these complex patients.1 Although previous clinical trials have demonstrated that baricitinib is an effective treatment for patients with active RA who are also receiving background methotrexate, a new analysis digs deeper into the data.

You Might Also Like
  • Biologic DMARDs Prove Effective for Psoriatic Arthritis & Combination DMARDs Show Promise for RA
  • Effectiveness of Tofacitinib with Methotrexate, Adalimumab Therapy Evaluated in Patients with RA
  • Baricitinib Also Appears Effective in Biologic-Refractory RA
Also By This Author
  • Gout Treatment & Care Remain Suboptimal

Arthur F. Kavanaugh, MD, professor of medicine at the University of California, San Diego, School of Medicine, presented the results of a post hoc analysis of two completed Phase 3 studies at the 2016 ACR/ARHP Annual Meeting in Washington, D.C.2 The research team sought to determine if previous failure of conventional disease-modifying anti-rheumatic drugs (cDMARDs) predicted an altered response to baricitinib in patients with RA. They also evaluated the effect of concomitant use of steroids and prognostically unfavorable factors on the efficacy of baricitinib.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Patients were randomized to receive placebo or baricitinib. Of the patients who received placebo, 40% had previously used methotrexate alone, 34% had used methotrexate and one cDMARD and 23% had used methotrexate plus two or more DMARDs. Of the patients who received 4 mg baricitinib, 46% had previously used methotrexate alone, 29% had used methotrexate plus one cDMARD and 23% had used methotrexate plus two or more DMARDs. At baseline, approximately half of the patients were using oral corticosteroids, and patients continued to use oral corticosteroids throughout the study.

The majority of each group (treatment or placebo) had two or three prognostically unfavorable factors. Nevertheless, 4 mg baricitinib was more effective than placebo. Specifically, the percentage of patients with a change from baseline in their van der Heijde modified Total Sharp Score (mTSS) of less than or equal to zero at 24 weeks was similar regardless of the other factors: number of cDMARDs previously used, concomitant use of corticosteroids or the presence of prognostically unfavorable factors.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Additionally, the rates of serious adverse events and discontinuation due to adverse events were comparable regardless of the other factors studied. Thus, baricitinib appears to be an effective treatment for patients who have a wide range of serologic status and baseline disease activity. In particular, baricitinib was effective in patients who had exposure to cDMARDs and corticosteroids.

If approved, baricitinib would join the oral JAK inhibitor tofacitinib  as a treatment for RA.3 Research has documented that tofacitinib given either 5 or 10 mg doses twice a day as monotherapy is superior to methotrexate monotherapy. This result was true whether the patients had early or established RA. That said, patients with early RA appeared to respond better at 24 months than did patients with established RA. There were no differences in the safety profiles for tofacitinib between patients with early or established RA.

Pages: 1 2 | Single Page

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: baricitinib, disease-modifying anti-rheumatic drugs, DMARDs, Janus Kinase Inhibitors, Methotrexate

You Might Also Like:
  • Biologic DMARDs Prove Effective for Psoriatic Arthritis & Combination DMARDs Show Promise for RA
  • Effectiveness of Tofacitinib with Methotrexate, Adalimumab Therapy Evaluated in Patients with RA
  • Baricitinib Also Appears Effective in Biologic-Refractory RA
  • Tofacitinib with Methotrexate Not Inferior to Adalimumab with Methotrexate

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)